Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged  ≥50 years: A randomized phase III trial (PNEU-PATH)

CONCLUSION: Administration of V114 followed by PPSV23 was well tolerated and induced comparable antibody levels to PCV13 followed by PPSV23 in healthy adults aged ≥50 years.PMID:34489128 | DOI:10.1016/j.vaccine.2021.08.038

https://pubmed.ncbi.nlm.nih.gov/34489128/?utm_source=no_user_agent&utm_medium=rs...

Source: Vaccine - September 7, 2021 Category: Allergy & Immunology Authors: Joon-Young Song Chih-Jen Chang Charles Andrews Javier Diez-Domingo Myoung-Don Oh Ron Dagan Jonathan Hartzel Alison Pedley Jianing Li Tina Sterling Gretchen Tamms Joseph A Chiarappa Jeannine Lutkiewicz Luwy Musey Yingmei Tu Ulrike K Buchwald V114-016 (PNEU Source Type: research

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged  ≥50 years: A randomized phase III trial (PNEU-PATH)